- Regeneron Pharmaceuticals press release ( NASDAQ: REGN ): Q2 Non-GAAP EPS of $9.77 beats by $1.02 .
- Revenue of $2.86B (-44.4% Y/Y) beats by $60M .
- EYLEA U.S. net sales increased 14% Y/Y to $1.62B.
- Dupixent global net sales increased 40% Y/Y to $2.09B.
- FDA approved Dupixent for atopic dermatitis in children aged 6 months to 5 years and eosinophilic esophagitis in adults and adolescents; FDA priority review granted for prurigo nodularis.
- FY2022, the company now expects adjusted gross margin on net product sales of 92% to 93% raised from prior outlook of 90% to 92%.
For further details see:
Regeneron Pharmaceuticals Non-GAAP EPS of $9.77 beats by $1.02, revenue of $2.86B beats by $60M